{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:59:07Z","timestamp":1790233147492,"version":"4.1.0"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004697","name":"Hamadan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.intimp.2020.106928","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T17:30:10Z","timestamp":1598290210000},"page":"106928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine"],"prefix":"10.1016","volume":"88","author":[{"given":"Rasoul","family":"Mirzaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokhsareh","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Badrzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Salimi","family":"Jeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Darvishmotevalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Yousefimashouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Karampoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"10.1016\/j.intimp.2020.106928_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105951","article-title":"Coronavirus disease 2019 (COVID-19): current status and future perspectives","volume":"55","author":"Li","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.106928_b0015","unstructured":"T.W.H. Organization, Coronavirus disease (COVID-19) pandemic, 2020. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"key":"10.1016\/j.intimp.2020.106928_b0020","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwaa036","article-title":"On the origin and continuing evolution of SARS-CoV-2","author":"Tang","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.intimp.2020.106928_b0025","article-title":"The symptoms, contagious process, prevention and post treatment of COVID-19","author":"Parvin","year":"2020","journal-title":"Europ. J. Physiotherapy Rehabilit. Stud."},{"key":"10.1016\/j.intimp.2020.106928_b0030","unstructured":"M.A. Ozma, P. Maroufi, E. Khodadadi, \u015e. K\u00f6se, I. Esposito, K. Ganbarov, S. Dao, S. Esposito, T. Dal, E. Zeinalzadeh10, Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (Covid-19) during the outbreak period, Inf. Med 28 (2020)."},{"issue":"18","key":"10.1016\/j.intimp.2020.106928_b0035","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2020.106928_b0040","doi-asserted-by":"crossref","DOI":"10.29333\/ejgm\/7850","article-title":"The possible immunological pathways for the variable immunopathogenesis of COVID\u201319 infections among healthy adults, elderly and children","volume":"17","author":"Abdulamir","year":"2020","journal-title":"Electron. J. General Med."},{"key":"10.1016\/j.intimp.2020.106928_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30244-9","article-title":"The many estimates of the COVID-19 case fatality rate","author":"Rajgor","year":"2020","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.intimp.2020.106928_b0050","series-title":"Features, evaluation and treatment coronavirus (COVID-19), Statpearls [internet]","author":"Cascella","year":"2020"},{"key":"10.1016\/j.intimp.2020.106928_b0055","unstructured":"U.S. Pharmacist, Three Strategies Emerging to Develop a COVID-19 Vaccine, 2020. https:\/\/www.uspharmacist.com\/article\/three-strategies-emerging-to-develop-a-covid19-vaccine."},{"key":"10.1016\/j.intimp.2020.106928_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","author":"Amanat","year":"2020","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"9","key":"10.1016\/j.intimp.2020.106928_b0070","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2217\/imt-2018-0213","article-title":"Are mimotope vaccines a good alternative to monoclonal antibodies?","volume":"11","author":"Pourjafar","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2020.106928_b0075","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106928_b0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response","volume":"14","author":"Astuti","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.intimp.2020.106928_b0085","article-title":"Genotype and phenotype of COVID-19: Their roles in pathogenesis","author":"Mousavizadeh","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"8","key":"10.1016\/j.intimp.2020.106928_b0090","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1128\/JVI.72.8.6838-6850.1998","article-title":"Coronavirus particle assembly: primary structure requirements of the membrane protein","volume":"72","author":"De Haan","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.106928_b0095","doi-asserted-by":"crossref","unstructured":"Y. Cong, M. Ulasli, H. Schepers, M. Mauthe, P. V\u2019kovski, F. Kriegenburg, V. Thiel, C.A. de Haan, F. Reggiori, Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle, J. Virol. 94(4) (2020).","DOI":"10.1128\/JVI.01925-19"},{"issue":"2","key":"10.1016\/j.intimp.2020.106928_b0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/422040","article-title":"Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid","volume":"190","author":"Leung","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"10223","key":"10.1016\/j.intimp.2020.106928_b0105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The lancet"},{"key":"10.1016\/j.intimp.2020.106928_b0110","first-page":"E005","article-title":"Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia, Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi=","volume":"43","author":"Chen","year":"2020","journal-title":"Chinese J. Tuberculosis Respiratory Dis."},{"issue":"SI-1","key":"10.1016\/j.intimp.2020.106928_b0115","first-page":"620","article-title":"COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs, Turk","volume":"50","author":"Tufan","year":"2020","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.intimp.2020.106928_b0120","article-title":"Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)","author":"Wan","year":"2020","journal-title":"MedRxiv"},{"issue":"11","key":"10.1016\/j.intimp.2020.106928_b0125","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.intimp.2020.106928_b0130","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2020.106928_b0135","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1086\/381535","article-title":"Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome","volume":"189","author":"Li","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.106928_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30120-X","article-title":"The immunology of COVID-19: is immune modulation an option for treatment?","author":"Zhong","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106928_b0145","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/21645515.2017.1389362","article-title":"Development of Middle East respiratory syndrome coronavirus vaccines\u2013advances and challenges","volume":"14","author":"Cho","year":"2018","journal-title":"Human Vacc. Immunother."},{"issue":"7","key":"10.1016\/j.intimp.2020.106928_b0150","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/erv.09.43","article-title":"SARS vaccines: where are we?","volume":"8","author":"Roper","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.intimp.2020.106928_b0155","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/03079450310001621198","article-title":"Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus","volume":"32","author":"Cavanagh","year":"2003","journal-title":"Avian Pathol."},{"issue":"11","key":"10.1016\/j.intimp.2020.106928_b0160","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1172\/JCI18819","article-title":"SARS coronavirus: a new challenge for prevention and therapy","volume":"111","author":"Holmes","year":"2003","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.intimp.2020.106928_b0165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/13550280490280292","article-title":"Coronavirus replication and pathogenesis: implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development","volume":"10","author":"Navas-Mart\u00edn","year":"2004","journal-title":"J. Neurovirol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106928_b0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.imlet.2004.06.014","article-title":"Immunogenicity of SARS inactivated vaccine in BALB\/c mice","volume":"95","author":"Xiong","year":"2004","journal-title":"Immunol. Lett."},{"issue":"2","key":"10.1016\/j.intimp.2020.106928_b0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbrc.2004.10.052","article-title":"Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry","volume":"325","author":"He","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2020.106928_b0180","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/intimm\/dxh143","article-title":"A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice","volume":"16","author":"Takasuka","year":"2004","journal-title":"Int. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106928_b0185","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.vaccine.2004.07.031","article-title":"Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice","volume":"23","author":"Qu","year":"2005","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.intimp.2020.106928_b0190","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3201\/eid1108.041003","article-title":"SARS vaccine protective in mice","volume":"11","author":"Stadler","year":"2005","journal-title":"Emerg. Infect. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0195","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1099\/vir.0.81579-0","article-title":"Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus","volume":"87","author":"See","year":"2006","journal-title":"J. Gen. Virol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106928_b0200","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/135965350701200702","article-title":"Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine","volume":"12","author":"Lin","year":"2007","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.intimp.2020.106928_b0205","first-page":"83","article-title":"Recombinant viruses as tools to induce protective cellular immunity against infectious diseases","volume":"7","author":"Rocha","year":"2004","journal-title":"Int. Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106928_b0210","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106928_b0215","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0952-7915(97)80104-5","article-title":"Recombinant viruses as vaccines and immunological tools","volume":"9","author":"Rolph","year":"1997","journal-title":"Curr. Opin. Immunol."},{"issue":"13","key":"10.1016\/j.intimp.2020.106928_b0220","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0264-410X(95)00032-V","article-title":"Adenovirus vectors as recombinant viral vaccines","volume":"13","author":"Imler","year":"1995","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.intimp.2020.106928_b0225","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1016\/j.vaccine.2007.04.065","article-title":"Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques","volume":"25","author":"Kobinger","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106928_b0230","series-title":"Development of protection against coronavirus induced diseases, Corona-and Related Viruses","first-page":"197","author":"Enjuanes","year":"1995"},{"issue":"4","key":"10.1016\/j.intimp.2020.106928_b0235","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/088282403771926292","article-title":"SARS: lessons learned from other coronaviruses","volume":"16","author":"Navas-Martin","year":"2003","journal-title":"Viral Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106928_b0240","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/1573395054065106","article-title":"Rapid response research-SARS coronavirus vaccines and application of processes to other emerging infectious diseases","volume":"1","author":"See","year":"2005","journal-title":"Curr. Immunol. Rev."},{"issue":"6965","key":"10.1016\/j.intimp.2020.106928_b0245","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2020.106928_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-1135(93)90126-R","article-title":"A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination","volume":"36","author":"Olsen","year":"1993","journal-title":"Vet. Microbiol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2020.106928_b0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0168-1702(96)01390-1","article-title":"Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies","volume":"46","author":"Ant\u00f3n","year":"1996","journal-title":"Virus Res."},{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0260","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.imlet.2004.01.001","article-title":"Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine","volume":"92","author":"Zhu","year":"2004","journal-title":"Immunol. Lett."},{"issue":"9","key":"10.1016\/j.intimp.2020.106928_b0265","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1128\/JVI.78.9.4638-4645.2004","article-title":"Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"Kim","year":"2004","journal-title":"J. Virol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2020.106928_b0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.imlet.2008.04.005","article-title":"A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro","volume":"119","author":"Wang","year":"2008","journal-title":"Immunol. Lett."},{"issue":"6982","key":"10.1016\/j.intimp.2020.106928_b0275","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature02463","article-title":"A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice","volume":"428","author":"Yang","year":"2004","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.intimp.2020.106928_b0280","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1016\/j.vaccine.2005.04.011","article-title":"Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines","volume":"23","author":"Zakhartchouk","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2020.106928_b0285","first-page":"459","article-title":"Comparative immunization in BALB\/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene","volume":"3","author":"Ma","year":"2006","journal-title":"Cell Mol. Immunol."},{"issue":"15","key":"10.1016\/j.intimp.2020.106928_b0290","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1128\/JVI.00304-08","article-title":"A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters","volume":"82","author":"Lamirande","year":"2008","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106928_b0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030109","article-title":"Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines","volume":"3","author":"Z\u00fcst","year":"2007","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.intimp.2020.106928_b0300","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/21645515.2017.1389362","article-title":"Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges","volume":"14","author":"Cho","year":"2018","journal-title":"Human Vacc. Immunother."},{"issue":"301","key":"10.1016\/j.intimp.2020.106928_b0305","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A synthetic consensus anti\u2013spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.106928_b0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-52768-7","article-title":"Evaluation of candidate vaccine approaches for MERS-CoV","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2020.106928_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112602","article-title":"Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen","volume":"9","author":"Lan","year":"2014","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.intimp.2020.106928_b0320","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.03","article-title":"Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus","volume":"13","author":"Zhang","year":"2016","journal-title":"Cell. Mol. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2020.106928_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081587","article-title":"A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines","volume":"8","author":"Du","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.106928_b0330","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2016.11.006","article-title":"T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV","volume":"137","author":"Liu","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.106928_b0335","doi-asserted-by":"crossref","first-page":"15092","DOI":"10.1038\/ncomms15092","article-title":"Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains","volume":"8","author":"Yuan","year":"2017","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2020.106928_b0340","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ebiom.2015.08.031","article-title":"Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge","volume":"2","author":"Lan","year":"2015","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.intimp.2020.106928_b0345","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.18632\/oncotarget.8475","article-title":"MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"46","key":"10.1016\/j.intimp.2020.106928_b0350","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1016\/j.vaccine.2014.08.086","article-title":"Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments\u2014the importance of immunofocusing in subunit vaccine design","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106928_b0355","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","article-title":"A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection","volume":"499","author":"Tai","year":"2016","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.intimp.2020.106928_b0360","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/21645515.2015.1021527","article-title":"Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus","volume":"11","author":"Tang","year":"2015","journal-title":"Human Vacc. Immunother."},{"issue":"26","key":"10.1016\/j.intimp.2020.106928_b0365","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2014.04.016","article-title":"Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice","volume":"32","author":"Coleman","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2020.106928_b0370","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2017.02.012","article-title":"MERS-CoV spike nanoparticles protect mice from MERS-CoV infection","volume":"35","author":"Coleman","year":"2017","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.intimp.2020.106928_b0375","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1128\/JVI.00614-15","article-title":"Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein","volume":"89","author":"Volz","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.106928_b0380","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci. Rep."},{"issue":"30","key":"10.1016\/j.intimp.2020.106928_b0385","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.intimp.2020.106928_b0390","doi-asserted-by":"crossref","first-page":"e00650","DOI":"10.1128\/mBio.00650-13","article-title":"Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate","volume":"4","author":"Almaz\u00e1n","year":"2013","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.intimp.2020.106928_b0395","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/088282403763635465","article-title":"Antibody-dependent enhancement of virus infection and disease","volume":"16","author":"Tirado","year":"2003","journal-title":"Viral Immunol."},{"key":"10.1016\/j.intimp.2020.106928_b0400","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3389\/fimmu.2018.00597","article-title":"Modulation of Dengue\/Zika virus pathogenicity by antibody-dependent enhancement and strategies to protect against enhancement in Zika virus infection","volume":"9","author":"Khandia","year":"2018","journal-title":"Front. Immunol."},{"issue":"Pt 6","key":"10.1016\/j.intimp.2020.106928_b0405","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1099\/0022-1317-70-6-1605","article-title":"Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence","volume":"70","author":"Gould","year":"1989","journal-title":"J. General Virol."},{"key":"10.1016\/j.intimp.2020.106928_b0410","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fcimb.2018.00044","article-title":"Antibody-dependent enhancement and Zika: real threat or phantom menace?","volume":"8","author":"Mart\u00edn-Acebes","year":"2018","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106928_b0415","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.106928_b0420","doi-asserted-by":"crossref","first-page":"102768","DOI":"10.1016\/j.ebiom.2020.102768","article-title":"Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development","volume":"55","author":"de Alwis","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2020.106928_b0425","first-page":"193","article-title":"Feline coronaviruses: pathogenesis of feline infectious peritonitis, Advances in virus research","author":"Tekes","year":"2016","journal-title":"Elsevier"},{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0430","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1128\/jvi.64.3.1407-1409.1990","article-title":"Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization","volume":"64","author":"Vennema","year":"1990","journal-title":"J. Virol."},{"issue":"3 Suppl 4","key":"10.1016\/j.intimp.2020.106928_b0435","first-page":"25","article-title":"Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS","volume":"22","author":"Yip","year":"2016","journal-title":"Hong Kong Med J"},{"issue":"7","key":"10.1016\/j.intimp.2020.106928_b0440","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1073\/pnas.1317454111","article-title":"Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue","volume":"111","author":"Chan","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2020.106928_b0445","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1073\/pnas.1324286111","article-title":"LILR-B1 blocks activating Fc\u03b3R signaling to allow antibody dependent enhancement of dengue virus infection","volume":"111","author":"Nimmerjahn","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2020.106928_b0450","doi-asserted-by":"crossref","first-page":"40923","DOI":"10.1038\/srep40923","article-title":"Dengue virus compartmentalization during antibody-enhanced infection","volume":"7","author":"Ong","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2020.106928_b0455","doi-asserted-by":"crossref","first-page":"e00528","DOI":"10.1128\/mSphere.00528-19","article-title":"Antibody-Dependent dengue virus entry modulates cell intrinsic responses for enhanced infection","volume":"4","author":"Chan","year":"2019","journal-title":"Msphere"},{"issue":"10169","key":"10.1016\/j.intimp.2020.106928_b0460","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue","volume":"393","author":"Wilder-Smith","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2020.106928_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.106928_b0470","first-page":"1","article-title":"The potential danger of suboptimal antibody responses in COVID-19","author":"Iwasaki","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"23","key":"10.1016\/j.intimp.2020.106928_b0475","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0480","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1073\/pnas.0409065102","article-title":"Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses","volume":"102","author":"Yang","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10224","key":"10.1016\/j.intimp.2020.106928_b0485","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0490","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/v12030254","article-title":"Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.intimp.2020.106928_b0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030525","article-title":"Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants","volume":"3","author":"Deming","year":"2006","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0500","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.cr.7290158","article-title":"Identification of an epitope of SARS-coronavirus nucleocapsid protein","volume":"13","author":"Ying","year":"2003","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2020.106928_b0505","doi-asserted-by":"crossref","unstructured":"J. Wang, J. Wen, J. Li, J. Yin, Q. Zhu, H. Wang, Y. Yang, E.d. Qin, B. You, W. Li, Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus, Clinical Chemistry 49(12) (2003) 1989-1996.","DOI":"10.1373\/clinchem.2003.023184"},{"issue":"12","key":"10.1016\/j.intimp.2020.106928_b0510","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.4049\/jimmunol.0903490","article-title":"Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study","volume":"186","author":"Tang","year":"2011","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.intimp.2020.106928_b0515","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.vaccine.2016.02.063","article-title":"Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection","volume":"34","author":"Ng","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106928_b0520","doi-asserted-by":"crossref","unstructured":"C.K.-f. Li, H. Wu, H. Yan, S. Ma, L. Wang, M. Zhang, X. Tang, N.J. Temperton, R.A. Weiss, J.M. Brenchley, T cell responses to whole SARS coronavirus in humans, J. Immunol. 181(8) (2008) 5490-5500.","DOI":"10.4049\/jimmunol.181.8.5490"},{"issue":"19","key":"10.1016\/j.intimp.2020.106928_b0525","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1128\/JVI.01505-14","article-title":"Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection","volume":"88","author":"Channappanavar","year":"2014","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0530","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106928_b0535","first-page":"446","article-title":"Evaluation by indirect immunofluorescent assay and enzyme linked immunosorbent assay of the dynamic changes of serum antibody responses against severe acute respiratory syndrome coronavirus","volume":"118","author":"Mo","year":"2005","journal-title":"Chin. Med. J."},{"issue":"2","key":"10.1016\/j.intimp.2020.106928_b0540","first-page":"119","article-title":"Immunological responses against SARS-coronavirus infection in humans","volume":"1","author":"Xu","year":"2004","journal-title":"Cell Mol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106928_b0545","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1128\/JVI.79.6.3401-3408.2005","article-title":"B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein","volume":"79","author":"Zhong","year":"2005","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106928_b0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000024","article-title":"Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus","volume":"1","author":"Li","year":"2006","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.106928_b0555","doi-asserted-by":"crossref","first-page":"102743","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.intimp.2020.106928_b0560","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12098","article-title":"Advances in antiviral vaccine development","volume":"255","author":"Graham","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2020.106928_b0565","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12979-020-00180-2","article-title":"Can an effective SARS-CoV-2 vaccine be developed for the older population?","volume":"17","author":"Pawelec","year":"2020","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.intimp.2020.106928_b0570","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00151-8","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2020.106928_b0575","unstructured":"BioSpace, The Hopes and Challenges of a COVID-19 Vaccine 2020. https:\/\/www.biospace.com\/article\/the-covid-19-vaccine-challenge-timelines-and-innovation\/."},{"key":"10.1016\/j.intimp.2020.106928_b0580","unstructured":"P. Vaccinations, Ad5-nCoV COVID-19 Vaccine, 2020. https:\/\/www.precisionvaccinations.com\/vaccines\/ad5-ncov-covid-19-vaccine."},{"key":"10.1016\/j.intimp.2020.106928_b0585","unstructured":"F.-C. Zhu, Y.-H. Li, X.-H. Guan, L.-H. Hou, W.-J. Wang, J.-X. Li, S.-P. Wu, B.-S. Wang, Z. Wang, L. Wang, S.-Y. Jia, H.-D. Jiang, L. Wang, T. Jiang, Y. Hu, J.-B. Gou, S.-B. Xu, J.-J. Xu, X.-W. Wang, W. Wang, W. Chen, Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial, The Lancet."},{"key":"10.1016\/j.intimp.2020.106928_b0590","unstructured":"clinicaltrials, A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV), 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04341389."},{"key":"10.1016\/j.intimp.2020.106928_b0595","unstructured":"clinicaltrials.gov, Safety and Immunity of Covid-19 aAPC Vaccine, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04299724."},{"key":"10.1016\/j.intimp.2020.106928_b0600","unstructured":"clinicaltrials.gov, Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA), 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04328441."},{"key":"10.1016\/j.intimp.2020.106928_b0605","unstructured":"T.I.V.I. (IVI), IVI, INOVIO, and KNIH to partner with CEPI in a Phase I\/II clinical trial of INOVIO\u2019s COVID-19 DNA vaccine in South Korea, 2020. https:\/\/www.ivi.int\/ivi-inovio-and-knih-to-partner-with-cepi-in-a-phase-i-ii-clinical-trial-of-inovios-covid-19-dna-vaccine-in-south-korea\/."},{"key":"10.1016\/j.intimp.2020.106928_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2020.106928_b0615","unstructured":"Sanofi, Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine, 2020. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-02-18-16-00-00."},{"issue":"1","key":"10.1016\/j.intimp.2020.106928_b0620","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.virusres.2007.03.025","article-title":"Animal models and vaccines for SARS-CoV infection","volume":"133","author":"Roberts","year":"2008","journal-title":"Virus Res."},{"issue":"9","key":"10.1016\/j.intimp.2020.106928_b0625","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1586\/14760584.2016.1167603","article-title":"Vaccines for the prevention against the threat of MERS-CoV","volume":"15","author":"Du","year":"2016","journal-title":"Expert review of vaccines"},{"issue":"7","key":"10.1016\/j.intimp.2020.106928_b0630","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3201\/eid1107.050219","article-title":"SARS vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.106928_b0635","doi-asserted-by":"crossref","first-page":"106717","DOI":"10.1016\/j.intimp.2020.106717","article-title":"Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses","volume":"86","author":"Gupta","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2020.106928_b0640","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.tips.2017.06.002","article-title":"An overview of novel adjuvants designed for improving vaccine efficacy","volume":"38","author":"Bonam","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"19","key":"10.1016\/j.intimp.2020.106928_b0645","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1016\/j.vaccine.2007.01.111","article-title":"Vaccine adjuvants revisited","volume":"25","author":"Aguilar","year":"2007","journal-title":"Vaccine"},{"issue":"6499","key":"10.1016\/j.intimp.2020.106928_b0650","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2020.106928_b0655","doi-asserted-by":"crossref","unstructured":"W. Ren, H. Sun, G.F. Gao, J. Chen, S. Sun, R. Zhao, G. Gao, Y. Hu, G. Zhao, Y. Chen, X. Jin, F. Fang, J. Chen, Q. Wang, S. Gong, W. Gao, Y. Sun, J. Su, A. He, X. Cheng, M. Li, C. Xia, M. Li, L. Sun, Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates, bioRxiv (2020) 2020.04.21.052209.","DOI":"10.1101\/2020.04.21.052209"},{"key":"10.1016\/j.intimp.2020.106928_b0660","doi-asserted-by":"crossref","unstructured":"N. van Doremalen, T. Lambe, A. Spencer, S. Belij-Rammerstorfer, J.N. Purushotham, J.R. Port, V. Avanzato, T. Bushmaker, A. Flaxman, M. Ulaszewska, ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques, bioRxiv (2020).","DOI":"10.1101\/2020.05.13.093195"},{"key":"10.1016\/j.intimp.2020.106928_b0665","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","author":"Zhu","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2020.106928_b0670","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","author":"Koch","year":"2020","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.intimp.2020.106928_b0675","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2016.09.008","article-title":"CoVaccine HT\u2122 adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1","volume":"439","author":"Lakhan","year":"2016","journal-title":"J. Immunol. Methods"},{"issue":"16","key":"10.1016\/j.intimp.2020.106928_b0680","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1128\/JVI.00549-10","article-title":"A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets","volume":"84","author":"Bodewes","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106928_b0685","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS ONE"},{"issue":"17","key":"10.1016\/j.intimp.2020.106928_b0690","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1016\/j.vaccine.2006.01.059","article-title":"A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice","volume":"24","author":"Zhou","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.106928_b0695","unstructured":"L. Bao, W. Deng, B. Huang, H. Gao, L. Ren, Q. Wei, P. Yu, Y. Xu, J. Liu, F. Qi, The pathogenicity of 2019 novel coronavirus in hACE2 transgenic mice. bioRxiv 2020, preprint 10.1101\/2020.02. 07.939389."},{"issue":"4","key":"10.1016\/j.intimp.2020.106928_b0700","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/CMR.00005-06","article-title":"Emerging respiratory viruses: challenges and vaccine strategies","volume":"19","author":"Gillim-Ross","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2020.106928_b0705","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/bbug.2.3.15367","article-title":"Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling","volume":"2","author":"Bowick","year":"2011","journal-title":"Bioengineered Bugs"},{"key":"10.1016\/j.intimp.2020.106928_b0710","unstructured":"clinicaltrials.gov, Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults (CTCOVID-19), 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04313127."},{"key":"10.1016\/j.intimp.2020.106928_b0715","unstructured":"clinicaltrials.gov, A Study of a Candidate COVID-19 Vaccine (COV001), 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04324606."},{"key":"10.1016\/j.intimp.2020.106928_b0720","unstructured":"clinicaltrials.gov, Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19), 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04283461."},{"key":"10.1016\/j.intimp.2020.106928_b0725","unstructured":"clinicaltrials.gov, Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04336410."},{"key":"10.1016\/j.intimp.2020.106928_b0730","unstructured":"clinicaltrials.gov, Immunity and Safety of Covid-19 Synthetic Minigene Vaccine, 2020. clinicaltrials.gov."},{"key":"10.1016\/j.intimp.2020.106928_b0735","unstructured":"clinicaltrials.gov, Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Frontline Healthcare Workers and First Responders, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04386252."},{"key":"10.1016\/j.intimp.2020.106928_b0740","unstructured":"clinicaltrials.gov, Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With\/Without Matrix-M Adjuvant, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368988."},{"key":"10.1016\/j.intimp.2020.106928_b0745","unstructured":"clinicaltrials.gov, Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334980."},{"key":"10.1016\/j.intimp.2020.106928_b0750","unstructured":"clinicaltrials.gov, Tableted COVID-19 Therapeutic Vaccine (COVID-19), 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04380532."},{"key":"10.1016\/j.intimp.2020.106928_b0755","unstructured":"clinicaltrialsregister.eu, Full Title: A Multi-site Phase I\/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens, 2020. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-001038-36."},{"key":"10.1016\/j.intimp.2020.106928_b0760","unstructured":"C.C.T.R. (ChiCTR), A randomized, double-blind, placebo parallel-controlled phase I\/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells), 2020. http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=52227."},{"key":"10.1016\/j.intimp.2020.106928_b0765","unstructured":"clinicaltrials.gov, Measles Vaccine in HCW (MV-COVID19), 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04357028."},{"key":"10.1016\/j.intimp.2020.106928_b0770","unstructured":"covid-vaccine-tracker, COVID-19 Vaccine & Therapeutics Tracker, 2020. https:\/\/biorender.com\/covid-vaccine-tracker\/details\/v-0CV3\/bacille-calmette-guerin-bcg."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920320464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920320464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:54:26Z","timestamp":1744505666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920320464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":154,"alternative-id":["S1567576920320464"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106928","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106928"}}